Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Canntab Therapeutics Ltd CTABF

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and... see more

Recent & Breaking News (GREY:CTABF)

CSE Bulletin: Delist - Canntab Therapeutics Limited (PILL)

Newsfile June 14, 2024

Canadian Investment Regulatory Organization Trading Halt - PILL

Canada NewsWire October 5, 2023

Canntab Therapeutics Limited Provides Update on Application for Management Cease Trade Order

Newsfile September 18, 2023

IIROC Trade Resumption - PILL

Canada NewsWire November 22, 2022

Canntab Announces Corporate Update

Accesswire November 22, 2022

IIROC Trading Halt - PILL

Canada NewsWire November 21, 2022

CANNTAB ANNOUNCES ITS ENTRANCE INTO THE NOVA SCOTIA CANNABIS MARKET

Canada NewsWire August 22, 2022

CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO

PR Newswire August 2, 2022

Canntab Corporate Update

PR Newswire June 30, 2022

CANNTAB ANNOUNCES CHANGE OF AUDITOR

PR Newswire May 30, 2022

Canntab Engages Hamish Sutherland as Strategic Advisor

PR Newswire April 13, 2022

CANNTAB SIGNS AFFILIATE AGRREMENT WITH ONPHARM-UNITED

PR Newswire March 23, 2022

CANNTAB SIGNS HISTORIC AGREEMENT WITH FIRST NATIONS GROWERS GP INC. TO ADDRESS THE OPIATE AND ILLICIT DRUG CRISIS AFFECTING INDIGENOUS PEOPLES THROUGHOUT CANADA

PR Newswire February 7, 2022

CANNTAB ANNOUNCES CLOSING OF CONVERTIBLE DEBENTURE PRIVATE PLACEMENT, WARRANT EXPIRY EXTENSION AND CORPORATE UPDATE

PR Newswire February 1, 2022

CANNTAB OFFICIALLY LAUNCHES ITS ONLINE E-COMMERCE PLATFORM

PR Newswire January 20, 2022

Levitee Labs (CSE:LVT) partners with Canntab Therapeutics (CSE:PILL)

Trevor Abes  January 10, 2022

Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids

GlobeNewswire January 10, 2022

CANNTAB DELIVERS 1st SHIPMENT TO THE ONTARIO CANNABIS STORE AND 2nd SHIPMENT TO AUSTRALIA

PR Newswire January 10, 2022

CANNTAB ENTERS INTO STRATEGIC PARTNERSHIP TO PROVIDE ALTERNATIVES TO OPIATES THROUGH LEVITEE CLINICS

PR Newswire December 16, 2021

Canntab Announces Agreement with Pathway Health

PR Newswire December 2, 2021